Trilostane for Androgen-Independent Prostate Cancer

Phase 2 Completed 24 enrolled Genzyme, a Sanofi Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.

Timeline

Start: 2004-03
Primary completion: 2006-01
Completion: 2006-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trilostane	Small molecule	—	Oral
Background	Hydrocortisone	Other / unclassified	—	Oral

Trilostane for Androgen-Independent Prostate Cancer

Summary

Timeline

Drugs

Indications